These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15364227)

  • 1. Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia.
    Ergun E; Heinzl H; Stur M
    Am J Ophthalmol; 2004 Sep; 138(3):434-8. PubMed ID: 15364227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia: long-term study.
    Pece A; Isola V; Vadalà M; Matranga D
    Retina; 2006 Sep; 26(7):746-51. PubMed ID: 16963846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation to age at treatment.
    Axer-Siegel R; Ehrlich R; Weinberger D; Rosenblatt I; Shani L; Yassur Y; Priel E; Kramer M
    Am J Ophthalmol; 2004 Oct; 138(4):602-7. PubMed ID: 15488787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.
    Verteporfin in Photodynamic Therapy Study Group
    Ophthalmology; 2001 May; 108(5):841-52. PubMed ID: 11320011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment frequency and visual outcome in subfoveal choroidal neovascularization related to pathologic myopia treated with photodynamic therapy.
    Maár N; Ergun E; Luksch A; Stur M
    Graefes Arch Clin Exp Ophthalmol; 2006 Oct; 244(10):1262-6. PubMed ID: 16538450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.
    Blinder KJ; Blumenkranz MS; Bressler NM; Bressler SB; Donato G; Lewis H; Lim JI; Menchini U; Miller JW; Mones JM; Potter MJ; Pournaras C; Reaves A; Rosenfeld P; Schachat AP; Schmidt-Erfurth U; Sickenberg M; Singerman LJ; Slakter JS; Strong HA; Virgili G; Williams GA
    Ophthalmology; 2003 Apr; 110(4):667-73. PubMed ID: 12689884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verteporfin photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia: a 12-month retrospective review.
    Costagliola C; Campa C; Incorvaia C; Parmeggiani F; Menzione M; Della Corte M; Rinaldi M; Romano M; Semeraro F
    Eur J Ophthalmol; 2008; 18(6):955-9. PubMed ID: 18988168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up.
    Lam DS; Chan WM; Liu DT; Fan DS; Lai WW; Chong KK
    Br J Ophthalmol; 2004 Oct; 88(10):1315-9. PubMed ID: 15377558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Verteporfin photodynamic therapy of choroidal neovascularization in angioid streaks: one-year results of a prospective case series.
    Browning AC; Chung AK; Ghanchi F; Harding SP; Musadiq M; Talks SJ; Yang YC; Amoaku WM;
    Ophthalmology; 2005 Jul; 112(7):1227-31. PubMed ID: 15921757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia: a long-term follow-up study.
    Pece A; Vadalà M; Isola V; Matranga D
    Am J Ophthalmol; 2007 Mar; 143(3):449-54. PubMed ID: 17317390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of coagulation-balance gene predictors on efficacy of photodynamic therapy for choroidal neovascularization in pathologic myopia.
    Parmeggiani F; Gemmati D; Costagliola C; Semeraro F; D'Angelo S; Perri P; Sebastiani A; Incorvaia C
    Ophthalmology; 2010 Mar; 117(3):517-23. PubMed ID: 20044141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
    Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2.
    Barbazetto I; Burdan A; Bressler NM; Bressler SB; Haynes L; Kapetanios AD; Lukas J; Olsen K; Potter M; Reaves A; Rosenfeld P; Schachat AP; Strong HA; Wenkstern A; ;
    Arch Ophthalmol; 2003 Sep; 121(9):1253-68. PubMed ID: 12963608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two years follow-up outcome of verteporfin therapy for subfoveal choroidal neovascularization in pathologic myopia in Indian eyes.
    Hussain N; Khanna R; Das T; Narayanan R; Sunday OT; Bansal AG; Reddy R
    Indian J Ophthalmol; 2008; 56(6):465-8. PubMed ID: 18974516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series.
    Saperstein DA; Rosenfeld PJ; Bressler NM; Rosa RH; Sickenberg M; Sternberg P; Aaberg TM; Aaberg TM; Reaves TA;
    Ophthalmology; 2002 Aug; 109(8):1499-505. PubMed ID: 12153802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes.
    Sickenberg M; Schmidt-Erfurth U; Miller JW; Pournaras CJ; Zografos L; Piguet B; Donati G; Laqua H; Barbazetto I; Gragoudas ES; Lane AM; Birngruber R; van den Bergh H; Strong HA; Manjuris U; Gray T; Fsadni M; Bressler NM
    Arch Ophthalmol; 2000 Mar; 118(3):327-36. PubMed ID: 10721954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.
    Bressler NM;
    Arch Ophthalmol; 2001 Feb; 119(2):198-207. PubMed ID: 11176980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of subfoveal choroidal neovascularization in pathologic myopia with photodynamic therapy: outcomes at 1 and 2 years of follow-up].
    El Matri L; Bouraoui R; Merdassi A; Baccouri R; Mghaieth F; Ben Rejeb S; Meddeb S
    J Fr Ophtalmol; 2006 Sep; 29(7):765-70. PubMed ID: 16988626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization.
    Spaide RF; Sorenson J; Maranan L
    Ophthalmology; 2003 Aug; 110(8):1517-25. PubMed ID: 12917166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 12-month retrospective study and review of photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration.
    Incorvaia C; Campa C; Parmeggiani F; Menzione M; D'Angelo S; Della Corte M; Rinaldi M; Romano M; Dell'omo R; Costagliola C
    Retina; 2008 Feb; 28(2):289-97. PubMed ID: 18301052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.